

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO DISTRIBUTION AGREEMENT
WITH YONGTAI PHARMACEUTICAL

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on December 31, 2024, the Company entered into a distribution agreement (the “**Agreement**”) with Zhejiang Yongtai Pharmaceutical Co., Ltd. (浙江永太藥業有限公司) (“**Yongtai Pharmaceutical**”), pursuant to which Yongtai Pharmaceutical agreed to grant to the Company a license to commercialize Gabapentin capsules (the “**Drug**”) in the United States.

Under the Agreement, the Company will purchase the Drug from Yongtai Pharmaceutical at an agreed price and will be responsible for the commercialization of the Drug in the United States market. No other payment is required from the Company to Yongtai Pharmaceutical besides the supply price for the Drug expressly set out in the Agreement.

INFORMATION ON GABAPENTIN

Gabapentin is a commonly used anticonvulsant medication and is widely utilized for the treatment of neuropathic pain and other painful conditions. The Drug’s possible mechanisms of action include influencing the synthesis and release of gamma-aminobutyric acid (GABA), binding to subunits of voltage-gated calcium channels and regulating glutamatergic neurons. In the United States, Gabapentin is officially used for the treatment of postherpetic neuralgia in adults and as an adjunctive therapy for partial seizures in patients aged 3 years and older. According to data from IQVIA, the sales of Gabapentin in the United States amounted to approximately US\$463 million for 2023.

BENEFITS AND IMPACTS TO THE COMPANY

This cooperation is the result of the careful consideration by the Company based on the combination of its development strategies and market research. As Yongtai Pharmaceutical is a modern comprehensive pharmaceutical company that integrates research and development, production and sales of oral solid formulations, active pharmaceutical ingredients and pharmaceutical intermediates, it has significant advantages in product quality and cost control, and the Drug has a promising market outlook. In the United States market, the Group can leverage its self-operated team which has rich sales experience and established self-operated sales networks and channels which allows for a full utilization of existing synergies in the sales model and channels for promoting the Drug.

The Company's strategic cooperation with Yongtai Pharmaceutical under the Agreement reflects the Group's strategy and commitment to international operations and its efforts in assisting Chinese pharmaceutical companies expand into the European and American markets. The Group has established comprehensive self-operated teams in five European countries and the United States, and has established self-operated sales networks and channels. This cooperation is a recognition of the Group's marketing capabilities in overseas markets and is an important opportunity for the Company to accumulate experience in marketing its products overseas, which has far-reaching and positive implications for the Group's future cooperations with other pharmaceutical companies.

INFORMATION ON YONGTAI PHARMACEUTICAL

Yongtai Pharmaceutical was established in the PRC in July 2012 and is a wholly-owned subsidiary of Zhejiang Yongtai Technology Co., Ltd. (浙江永太科技股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 002326). Yongtai Pharmaceutical is located in the Linhai Industrial Park, a base for chemical pharmaceutical raw materials in Zhejiang Province of the PRC, and is a modern comprehensive pharmaceutical company that integrates research and development, production and sales of oral solid formulations, active pharmaceutical ingredients and pharmaceutical intermediates.

Announcement is hereby given.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
January 2, 2025

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.